TABLE 2.
Clinical features and cerebrospinal fluid findings.
| Variable |
N = 105 |
|||||
|---|---|---|---|---|---|---|
| Mean | s.d. | Median | IQR | n | % | |
| Positive screening serum CrAg – No | - | - | - | - | 9 | 8.6 |
| Headache – No | - | - | - | - | 96 | 91.4 |
| Low GCS – No | - | - | - | - | 34 | 32.4 |
| Seizures – No | - | - | - | - | 5 | 4.8 |
| Focal neurology – No | - | - | - | - | 10 | 9.5 |
| Skin rash – No | - | - | - | - | 17 | 16.2 |
| Cerebrospinal fluid analysis | - | - | - | - | - | - |
| Protein – Mean (s.d.) g/L | 1.15 | 1.0 | - | - | - | - |
| Glucose – Mean (s.d.) mmol/L | 2.40 | 1.50 | - | - | - | - |
| Lymphocytes – Median (IQR)/µL | - | - | 9.0 | 2–64 | - | - |
| Polymorphonuclear cells – Median (IQR)/µL | - | - | 3.00 | 0–9.0 | - | - |
| Positive CrAg – No | - | - | - | - | 105 | 100 |
| Positive India Ink – No | - | - | - | - | 84 | 80.0 |
| Positive culture for cryptococcus neoformans – No | - | - | - | - | 99 | 94.3 |
| In-hospital therapy | - | - | - | - | - | - |
| Amphotericin B plus fluconazole – No | - | - | - | - | 103 | 98.1 |
| Amphotericin B only – No | - | - | - | - | 2 | 1.9 |
| Therapeutic lumbar punctures | 4.62 | 2.30 | - | - | - | - |
| Number of days in hospital | 19.4 | 8.3 | - | - | - | - |
| In-hospital mortality – No | - | - | - | - | 23 | 21.9 |
CrAg, cryptococcal antigen; GCS, GCS, Glasgow Coma Scale; s.d., standard deviation; IQR, interquartile range.